EcoDrugPlus

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSMLUG00000009608
Gene Symbol: CYP26A1
2 Cross references
207 Possible Orthologues:

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSMLUG00000006571
Gene Symbol: CYP46A1
2 Cross references
259 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSMLUG00000002332
Gene Symbol: DGAT1
2 Cross references
260 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSMLUG00000013861
Gene Symbol: DHODH
2 Cross references
173 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSMLUG00000005319
Gene Symbol: DDR2
2 Cross references
265 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSMLUG00000017069
Gene Symbol: DRD1
2 Cross references
261 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSMLUG00000011890
Gene Symbol: DRD2
2 Cross references
219 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSMLUG00000004740
Gene Symbol: DRD3
2 Cross references
206 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSMLUG00000013453
Gene Symbol: DRD5
2 Cross references
186 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSMLUG00000006285
Gene Symbol: ENPP2
2 Cross references
227 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSMLUG00000000224
Gene Symbol: EGLN2
2 Cross references
190 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSMLUG00000014716
Gene Symbol: EGLN3
2 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).